FOUR WAYS TO REMAIN VIGILANT ABOUT COVID-19

Your Health
COVID-19_July_4_790x500.jpg
COVID-19_July_4_1000x450.jpg

FOUR WAYS TO REMAIN VIGILANT ABOUT COVID-19

How you can keep yourself and your family safe this summer and minimize the spread of the coronavirus.

RENEWED COMMITMENT TO GAVI, THE VACCINE ALLIANCE

Our Purpose
Pfizer_UgandA_Rwanda_Trip_2016-584_380x500
Pfizer_UgandA_Rwanda_Trip_2016-584_1000x450.jpg

RENEWED COMMITMENT TO GAVI, THE VACCINE ALLIANCE

As healthcare systems around the world face unprecedented challenges, the fight against infectious diseases is more important than ever. 

THE ANTIGEN: COVID-19 PODCAST

Podcasts
the_antigen_podcast_image_300x400_1.png
the_antigen_podcast_image_1000x450_1.jpg

THE ANTIGEN: COVID-19 PODCAST

The Antigen podcast is back with a special mini-series focused on COVID-19.

PARTNERING WITH DIRECT RELIEF TO PROVIDE COVID-19 SUPPLIES TO HOSPITALS

Our Purpose
DSC07402_790x500.png
DSC07402_1000x450.jpg

PARTNERING WITH DIRECT RELIEF TO PROVIDE COVID-19 SUPPLIES TO HOSPITALS

We have always been committed to deploying our resources in times of crisis, and we leveraged our long-standing partnership with Direct Relief to help alleviate issues facing hospitals.

Find a Trial

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

MANUFACTURING AND GLOBAL SUPPLY CAPABILITIES

News
PGS_COVID_FIH_380x700.png
PGS_COVID_FIH_1000x450.png

MANUFACTURING AND GLOBAL SUPPLY CAPABILITIES

How we are scaling up to manufacture and supply a COVID-19 vaccine, if approved.

Age: Addressing a Blind Spot in Cancer Care

Our Purpose
Health Equity Article_790x500_0.png
Health Equity Article_1000x450_0.jpg

Age: Addressing a Blind Spot in Cancer Care

At Pfizer, we're focused on removing barriers for all people living with cancer - including those over the age of 65 - to address disparities in cancer carr and improve health equity.

Latest News

Anticipated large, global Phase 2b/3 safety and efficacy study may begin as early as July 2020 Pfizer Inc . (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that two of the companies’ four investigational vaccine candidates from their BNT162 mRNA-based vaccine program (BNT162b1 and BNT162b2) being developed to help protect against SARS-CoV-2 (the virus that causes COVID-19), received Fast Track designation from the U.S. Food and Drug Administration (FDA). BNT162b1 and…